Catheter Precision, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Catheter Precision, Inc. designs, manufactures, and sells advanced medical devices focused on the cardiac electrophysiology market. Its core products include the VIVO™ non-invasive 3D cardiac mapping system that aids in localizing the origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts, and the LockeT suture retention device, which facilitates secure suture retention and removal in clinical settings. The company’s proprietary MAMMOTH™ electrophysiology catheter system offers real-time 3D visualization of the catheter tip, enhancing precision and safety during cardiac procedures. Catheter Precision targets healthcare providers and institutions specializing in cardiac care, operating primarily in the United States with expanding presence in international markets including Central and Eastern Europe. Founded in 2002 and headquartered in Fort Mill, South Carolina, Catheter Precision recently secured a significant tender with Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary, marking a strategic expansion into Central European markets. It has also received first purchase orders from hospitals in Croatia and increased orders within the U.S., notably from Eisenhower Medical Center, UCLA Medical Center, and Rady Children’s Hospital in California, supporting the national launch of its LockeT device. The company completed the acquisition of Cardionomic’s heart failure assets, which includes the CPNS system targeting heart failure treatment. These developments underscore Catheter Precision’s focus on broadening its product portfolio while growing its commercial footprint and clinical team internationally. Catheter Precision operates within the medical device industry, specifically in electrophysiology and cardiac intervention segments. It emphasizes innovation, safety, and efficiency in its technologies designed to improve patient outcomes in cardiac arrhythmia interventions. The company is publicly listed on the NYSE American exchange under the ticker VTAK and maintains a workforce of approximately 20-50 employees. Its strategic initiatives in the last 1-2 years include product launches, expanded sales and clinical teams, international tender wins, and targeted acquisitions to enhance its offerings and market reach. This comprehensive product and operational strategy positions Catheter Precision, Inc. as a growing player in the global cardiac electrophysiology device market with a commitment to delivering innovative solutions that advance the standard of patient care.
Company News
Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean
Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany
Flyte Surpasses 10,000 Consumer Accounts as WebApp Growth Accelerates
Flyte Partners with FullPAC to Bring Regional Aviation to the $11.4 Billion U.S. Political Campaign Market
Flyte Partners with The Nucleus Network for Inaugural Flagship Founder & Investor Event
Flyte Achieves Record Revenues in July
Flyte Partners with Volato AI to Become First Enterprise Customer, Accelerating Technology Strategy to Scale Regional Private Aviation
Volato AI Launches with Flyte as First Enterprise Customer
Flyte Partners with LDV at The Maidstone to Elevate Luxury Travel to the Hamptons
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
Aviation Stocks Lift Off: Flyte (VTAK) Teams Up with Blade Urban Air Mobility
Flyte Partners with Blade to Expand Vision Jet Distribution
Flyte Partners with LifeVac to Equip Every Vision Jet with Life-Saving Equipment
Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform
FLYTE EXPANDS STRATEGIC RELATIONSHIP WITH VOLATO BY JOINING VAUNT PLATFORM
Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)
Volato Group Announces $2.2 Million Strategic Investment and AI Infrastructure Acquisition Focus
FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND
FLYTE ACTIVATES HIGH-FREQUENCY PREAKNESS FLIGHT PROGRAM, DEPLOYING FLEET TO SERVE STRONG NORTHEAST DEMAND
Flyte Increases Capacity and Launches Hiring Initiative as Spirit Airlines Shutdown Disrupts U.S. Air Travel